Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Five Prime Therapeutics to Participate in the 38th Annual J.P. Morgan Healthcare Conference


Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, will participate in the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020. William Ringo, who is Five Prime's Chairman and interim Chief Executive Officer, will represent the company and respond to questions from investors. He is scheduled to present at 7:30 a.m. PT (10:30 a.m. ET).

Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.fiveprime.com/events-presentations. A replay of the presentation will also be available on the Five Prime website for 30 days after the conference.

About Five Prime

Five Prime Therapeutics, Inc. develops innovative protein therapeutics to improve the lives of patients with cancer. The company focuses on developing immune modulators and precision therapies for solid tumor cancers paired with companion diagnostics to identify patients who are most likely to benefit from treatment with Five Prime's product candidates. The company's product candidates have innovative mechanisms of action and address patient populations in need of better therapies. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com.

Source: Five Prime Therapeutics, Inc.


These press releases may also interest you

at 12:24
West Physics Announces Acquisition of Tricord, Inc.
West Physics Consulting, LLC ("West Physics"), the leading national provider of integrated medical and health physics services, announced today that it has completed the purchase of the medical physics service division of Tricord, Inc. ("Tricord"), a...

at 12:16
Amae Health, Innovative Treatment Provider for Severe Mental Illness, Announces Closing of Oversubscribed $15 Million Series A Funding Round
Amae Health, a trailblazer in delivering patient-centered care for people with severe mental illness, announced today the successful closing of its oversubscribed $15 million Series A funding round. The round was led by Quiet Capital and included...

at 12:08
Roivios Secures FDA Breakthrough Device Designation for JuxtaFlow® RAD, Showcases Pioneering Data at Society of Cardiovascular Anesthesiologists Annual Meeting
Roivios, a pioneering clinical-stage medical device company dedicated to transforming kidney health, is thrilled to announce it has been awarded the prestigious Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its...

at 12:06
Burrell College of Osteopathic Medicine Achieves Highest Accreditation Status from AOA Commission on Osteopathic College Accreditation
Burrell College of Osteopathic Medicine (BCOM) attained the highest level of accreditation from the American Osteopathic Association (AOA) Commission on Osteopathic College Accreditation (COCA). Burrell has been awarded the prestigious accreditation...

at 12:05
Radiance Biopharma to Present at LSX World Congress 2024
Radiance Biopharma ("Radiance" or the "Company"), a biopharmaceutical company specializing in the development of novel Antibody Drug Conjugates (ADCs) and Bispecific ADCs (BsADCs) treatments for cancers, today announced that...

at 12:01
Report from Orexo AB's annual general meeting, 26 April 2024
Election of the board of directors and auditor The annual general meeting in Orexo AB (publ) on 26 April 2024 resolved, in accordance with the nomination committee's proposal, that the number of board members shall be five with no deputy board...

More news about Health...


News published on and distributed by: